Press-release for stocks related to drug

Prices are updated after-hours

approved tags : Drug

save search

FDA Approves Vanda Schizophrenia Drug for Bipolar I Disorder
Published: 2024-04-03 (Crawled : 13:30) - biospace.com/
PRGO | $30.04 0.27% 0.0% 780K

Health Technology

| -4.09% | O: -0.29% H: 1.34% C: -0.64%
JNJ | News | $144.77 0.22% -0.01% 9.3M

Health Technology

| -8.22% | O: 0.02% H: 0.0% C: 0.0%
ABT | News | $105.9 -3.03% 0.07% 12M

Health Technology

| -3.65% | O: 0.11% H: 0.37% C: -0.77%
SNY | News | $46.125 0.71% 0.7% 3.7M

Health Technology

| -3.33% | O: 0.69% H: 0.0% C: 0.0%
fda drug schizophrenia

U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
Published: 2024-03-22 (Crawled : 19:00) - prnewswire.com
ABBV | $164.25 1.05% -0.76% 4M

Health Technology

| Email alert Add to watchlist
elahere drug approval food cancer grants

FDA Approves Takeda’s Iclusig for Type of Leukemia, Idorsia’s Hypertension Drug
Published: 2024-03-21 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.116 -2.18% 2.3K

Health Technology

| -2.29% | O: 0.14% H: 0.24% C: 0.24%
PRGO | $30.04 0.27% 0.0% 780K

Health Technology

| -4.03% | O: 0.0% H: 1.6% C: 0.89%
JNJ | News | $144.77 0.22% -0.01% 9.3M

Health Technology

| -6.95% | O: -0.03% H: 0.0% C: 0.0%
ABT | News | $105.9 -3.03% 0.07% 12M

Health Technology

| -4.17% | O: -0.56% H: 0.0% C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M

Health Technology

| -2.56% | O: 0.3% H: 0.0% C: 0.0%
fda drug iclusig hypertension

Idorsia Wins FDA Approval in Hypertension Months After J&J Returned Rights to Drug
Published: 2024-03-21 (Crawled : 12:30) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M

Health Technology

| -6.95% | O: -0.03% H: 0.0% C: 0.0%
fda drug approval hypertension

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | $13.15 -0.61% 0.0% 1.6M

Health Technology

| -9.68% | O: -0.07% H: 0.0% C: -0.96%
iclusig fda drug takeda approval application

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB®
Published: 2024-03-18 (Crawled : 14:00) - biospace.com/
SCLX | $1.17 0.86% 0.85% 470K

| -14.6% | O: -0.73% H: 3.31% C: 0.74%
elyxyb drug patent company health approval review canada submission

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada
Published: 2024-03-18 (Crawled : 13:00) - globenewswire.com
SCLX | $1.17 0.86% 0.85% 470K

| -14.6% | O: -0.73% H: 3.31% C: 0.74%
elyxyb drug patent company health approval review treatment canada migraine submission

FDA Decisions: Wegovy Approved for CV Indication; Viatris and Mapi’s MS Drug ...
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
PRGO | $30.04 0.27% 0.0% 780K

Health Technology

| -0.69% | O: 0.0% H: 2.38% C: 1.12%
JNJ | News | $144.77 0.22% -0.01% 9.3M

Health Technology

| -8.91% | O: 0.43% H: 0.0% C: 0.0%
ABT | News | $105.9 -3.03% 0.07% 12M

Health Technology

| -10.65% | O: 0.26% H: 0.0% C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M

Health Technology

| -4.06% | O: 0.57% H: 0.0% C: 0.0%
fda drug wegovy approved

FDA Decisions: Wegovy Approved for CV Indication; Viatris and Mapi’s MS Drug Rejected
Published: 2024-03-11 (Crawled : 14:30) - biospace.com/
PRGO | $30.04 0.27% 0.0% 780K

Health Technology

| -0.69% | O: 0.0% H: 2.38% C: 1.12%
JNJ | News | $144.77 0.22% -0.01% 9.3M

Health Technology

| -8.91% | O: 0.43% H: 0.0% C: 0.0%
ABT | News | $105.9 -3.03% 0.07% 12M

Health Technology

| -10.65% | O: 0.26% H: 0.0% C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M

Health Technology

| -4.06% | O: 0.57% H: 0.0% C: 0.0%
fda drug wegovy approved

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
TVTX | $5.99 -2.6% -2.67% 1.3M

Health Technology

| -30.83% | O: -0.81% H: 1.51% C: -6.98%
filspari nephropathy drug approval food treatment application therapeutics

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
Published: 2024-03-10 (Crawled : 00:00) - globenewswire.com
MESO | $5.03 7.25% 6.76% 500K

Health Technology

| 133.02% | O: 16.28% H: 27.6% C: 6.4%
drug device approval food heart

FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’sAgency to convene an advisory committee to consider the drug
Published: 2024-03-08 (Crawled : 15:30) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M

Health Technology

| -3.77% | O: -0.02% H: 0.0% C: -2.29%
fda drug approval treatment

Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
Published: 2024-03-01 (Crawled : 15:00) - biospace.com/
MNKKQ | $0.02

Manufacturing

| Email alert Add to watchlist
MNK | $0.3402 -0.06% 540K

n/a

| Email alert Add to watchlist
MNKPF | $17.25

n/a

| Email alert Add to watchlist
MNKTQ | $0.12 -66.67% 39K

Manufacturing

| Email alert Add to watchlist
acthar fda drug approval gel application

Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
Published: 2024-02-22 (Crawled : 00:00) - biospace.com/
LGND | News | $78.93 -1.24% -1.25% 180K

Health Technology

| 8.53% | O: -0.32% H: 2.15% C: 1.55%
CPRX | $15.99 2.9% 2.81% 1.4M

Health Technology

| 13.35% | O: -0.07% H: 2.3% C: 1.46%
fycompa drug japan approval injection

Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya™ for the Management of Fibromyalgia
Published: 2024-02-13 (Crawled : 13:00) - globenewswire.com
TNXP | $0.1581 5.47% 5.19% 2M

Health Technology

| -56.76% | O: 1.81% H: 0.88% C: -6.29%
fda management drug fibromyalgia approval pharmaceuticals application submission

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
Published: 2024-01-31 (Crawled : 14:30) - biospace.com/
VNDA | News | $5.23 29.14% 22.56% 24M

Health Technology

| 43.56% | O: 1.37% H: 1.35% C: -2.7%
vtr-297 fda drug candidate approval treatment pharmaceuticals antifungal

Breast Cancer Therapeutics Market 2023, USD 15.64 billion Growth is Expected between 2023 to 2028, Robust pipeline and new drug approvals to Boost Growth - Technavio
Published: 2024-01-30 (Crawled : 18:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| 4.69% | O: 5.68% H: 0.77% C: 0.77%
AZNCF | $135.305 -4.19% 1.1K

Health Technology

| 3.09% | O: 3.41% H: 0.0% C: -2.45%
VTRS | $11.095 -0.22% -0.23% 6.1M

Health Technology

| -6.01% | O: -0.08% H: 3.47% C: -0.25%
NVS | News | $93.08 -0.13% 0.86% 1.2M

Health Technology

| -13.61% | O: -2.04% H: 0.19% C: -1.97%
GSK | $39.6 -0.88% 0.0% 2.8M

Health Technology

| 1.3% | O: 4.04% H: 1.57% C: -3.02%
ABBV | $164.25 1.05% -0.76% 4M

Health Technology

| -0.41% | O: 0.5% H: 0.07% C: -0.81%
SNY | News | $46.125 0.71% 0.7% 3.7M

Health Technology

| -8.28% | O: 1.75% H: 0.0% C: 0.0%
PBYI | $5.18 1.57% 1.54% 250K

Health Technology

| 8.5% | O: -0.1% H: 2.31% C: -1.26%
AZN | $68.53 0.39% 0.39% 3.7M

Health Technology

| 1.58% | O: 0.82% H: 0.12% C: -1.64%
AMGN | $264.07 -0.59% -0.59% 2.2M

Health Technology

| -15.16% | O: 0.44% H: 0.2% C: -0.55%
drug breast expected cancer pipeline therapeutics growth market

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
Published: 2024-01-23 (Crawled : 15:30) - biospace.com/
VNDA | News | $5.23 29.14% 22.56% 24M

Health Technology

| 38.26% | O: 2.11% H: 1.03% C: -4.13%
vca-894 fda drug candidate approval treatment pharmaceuticals

FDA Decisions: J&J's Bladder Cancer Drug Wins Full Approval
Published: 2024-01-22 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.116 -2.18% 2.3K

Health Technology

| -8.68% | O: 1.71% H: 0.0% C: -0.15%
PRGO | $30.04 0.27% 0.0% 780K

Health Technology

| -9.22% | O: 0.36% H: 2.11% C: 1.29%
JNJ | News | $144.77 0.22% -0.01% 9.3M

Health Technology

| -10.08% | O: 0.6% H: 0.0% C: 0.0%
ABT | News | $105.9 -3.03% 0.07% 12M

Health Technology

| -5.27% | O: 0.88% H: 0.0% C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M

Health Technology

| -10.01% | O: -0.21% H: 0.0% C: 0.0%
fda drug approval bladder cancer

J&J Secures Full FDA Approval for Bladder Cancer Drug Balversa
Published: 2024-01-22 (Crawled : 13:30) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M

Health Technology